Search Results | Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Abstract 5744: Characterization of sideness-related differentiated genetic alterations in stage I-IV colorectal cancer patients by using whole exome sequencing

Danyi Wang, Lee McDaniel, Sean Boyle, Giuseppe Locatelli, Juergen Scheuenpflug, Zheng Feng

Cancer Res (2022) 82 (12_Supplement): 5744.

DOI: https://doi.org/10.1158/1538-7445.AM2022-5744

Published: 15 June 2022

View article

Journal Articles

Abstract 2062: Comprehensive molecular profiling of DNA damage response (DDR) deficiencies in advanced solid tumors using a real-world genomic database

Danyi Wang, Brian Elenbaas, Karthikeyan Murugesan, Lee A. Albacker, Julien Doudement, Juergen Scheuenpflug, Giuseppe Locatelli, Zheng Feng

Cancer Res (2021) 81 (13_Supplement): 2062.

DOI: https://doi.org/10.1158/1538-7445.AM2021-2062

Published: 01 July 2021

View article

Journal Articles

Abstract 4663: Combination of c-Met inhibitor tepotinib (MSC2156119J) and a third-generation EGFR inhibitor can overcome double resistance mediated by EGFR T790M mutation and c-Met amplification in non-small cell lung cancer models

Manja Friese-Hamim, Giuseppe Locatelli, Friedhelm Bladt

Cancer Res (2016) 76 (14_Supplement): 4663.

DOI: https://doi.org/10.1158/1538-7445.AM2016-4663

Published: 15 July 2016

View article

Journal Articles

Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

Jeffrey R. Infante, Leena Gandi, Geoffrey Shapiro, Naiyer Rizvi, Howard A. Burris, Johanna C. Bendell, José Baselga, Karl Hsu, Oliver von Richter, Giuseppe Locatelli, Ekaterine Asatiani, Rebecca S. Heist

Cancer Res (2013) 73 (8_Supplement): LB-147.

DOI: https://doi.org/10.1158/1538-7445.AM2013-LB-147

Published: 15 April 2013

View article

Journal Articles

Abstract #5445: Biomarker analysis by gene expression profiling of tumor and skin biopsies from a Phase I clinical study with the CDK inhibitor PHA-793887

Giuseppe Locatelli, Roberta Bosotti, Marina Ciomei, Wilma Pastori, Matteo Bertolotti, Emanuela Scacheri, Angela Scaburri, Enrico Pesenti, Thierry De Baere, Jean-Charles Soria, Vladimir Lazar, Antonella Isacchi

Cancer Res (2009) 69 (9_Supplement): 5445.

Published: 01 May 2009

View article

Journal Articles

Phosphorylation of the Eukaryotic Initiation Factor eIF4E contributes to the translation of specific immediate early genes

Marisa Montemartini, Giovanna Ficalora, Claudia Perrera, Giuseppe Locatelli, Fabio Gasparri, Paola magnaghi

Cancer Res (2008) 68 (9_Supplement): 178.

Published: 01 May 2008

View article

Journal Articles

Normal skin as surrogate tissue for studying the mechanism of action of cell cycle inhibitors

Rachele Alzani, Roberta Ceruti, Giuseppe Locatelli, Clara Albanese, Veronica Patton, Marina Ciomei, Enrico Pesenti, James R. Bischoff, Ciro Mercurio

Cancer Res (2004) 64 (7_Supplement): 603.

Published: 01 April 2004

View article

NARROW

Abstract 5744: Characterization of sideness-related differentiated genetic alterations in stage I-IV colorectal cancer patients by using whole exome sequencing

Abstract 2062: Comprehensive molecular profiling of DNA damage response (DDR) deficiencies in advanced solid tumors using a real-world genomic database

Abstract 4663: Combination of c-Met inhibitor tepotinib (MSC2156119J) and a third-generation EGFR inhibitor can overcome double resistance mediated by EGFR T790M mutation and c-Met amplification in non-small cell lung cancer models

Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

Abstract #5445: Biomarker analysis by gene expression profiling of tumor and skin biopsies from a Phase I clinical study with the CDK inhibitor PHA-793887

Phosphorylation of the Eukaryotic Initiation Factor eIF4E contributes to the translation of specific immediate early genes

Normal skin as surrogate tissue for studying the mechanism of action of cell cycle inhibitors

Email alerts

AACR Journals

Abstract 5744: Characterization of sideness-related differentiated genetic alterations in stage I-IV colorectal cancer patients by using whole exome sequencing

Abstract 2062: Comprehensive molecular profiling of DNA damage response (DDR) deficiencies in advanced solid tumors using a real-world genomic database

Abstract 4663: Combination of c-Met inhibitor tepotinib (MSC2156119J) and a third-generation EGFR inhibitor can overcome double resistance mediated by EGFR T790M mutation and c-Met amplification in non-small cell lung cancer models

Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

Abstract #5445: Biomarker analysis by gene expression profiling of tumor and skin biopsies from a Phase I clinical study with the CDK inhibitor PHA-793887

Phosphorylation of the Eukaryotic Initiation Factor eIF4E contributes to the translation of specific immediate early genes

Normal skin as surrogate tissue for studying the mechanism of action of cell cycle inhibitors

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only